These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36325753)

  • 1. A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout.
    Lee J; Kim J; Ghang B; Jeong W
    Korean J Intern Med; 2023 May; 38(3):427-433. PubMed ID: 36325753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
    Shen M; Zhang J; Qian K; Li C; Xu W; Gu B; Wang X; Ren Q; Yang L; Yuan H; Su D; Chen X
    Clin Rheumatol; 2018 Nov; 37(11):3107-3113. PubMed ID: 30196323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Febuxostat for treating chronic gout.
    Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
    Zhou Q; Su J; Zhou T; Tian J; Chen X; Zhu J
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):163-168. PubMed ID: 27936522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
    Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database.
    So MW; Kim AR; Lee SG
    Int J Rheum Dis; 2023 Sep; 26(9):1770-1778. PubMed ID: 37431263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the therapeutic effects of febuxostat combined with a low-purine diet and allopurinol combined with a low-purine diet on the improvement of gout patients.
    Chen X; Ye T; Dai Y; Li P; Zhao X; Yu Y; Wang X; Jiao X; Shen N
    Int J Rheum Dis; 2024 May; 27(5):e15165. PubMed ID: 38769820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
    Kim SH; Lee SY; Kim JM; Son CN
    Korean J Intern Med; 2020 Jul; 35(4):998-1003. PubMed ID: 30959584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
    Wang S
    Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
    Yamanaka H; Tamaki S; Ide Y; Kim H; Inoue K; Sugimoto M; Hidaka Y; Taniguchi A; Fujimori S; Yamamoto T
    Ann Rheum Dis; 2018 Feb; 77(2):270-276. PubMed ID: 29102957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of febuxostat in gout patients on dialysis.
    Choi SY; Choi SW; Lee S; So MW; Oh JS; Lim DH
    Intern Med J; 2021 Mar; 51(3):348-354. PubMed ID: 32043690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Quilisadio JEC; Salido EO; Penserga EG
    Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3.
    Novella-Navarro M; Cabrera-Alarcon JL; Diaz-Torne C; Aramburu-Muñoz F; Janta I; Ortega de la O MC; Prada-Ojeda A; Sala-Icardo L; Urruticoechea-Arana A; García de la Peña Lefebvre P; Calvo-Aranda E
    Rheumatol Int; 2020 Jul; 40(7):1081-1087. PubMed ID: 31982955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
    Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG
    Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
    Wu J; Zhang YP; Qu Y; Jie LG; Deng JX; Yu QH
    Int J Rheum Dis; 2019 Aug; 22(8):1445-1451. PubMed ID: 31317680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
    Perez-Ruiz F; Chinchilla SP; Atxotegi J; Urionagüena I; Herrero-Beites AM; Aniel-Quiroga MA
    Rheumatol Int; 2015 Nov; 35(11):1857-61. PubMed ID: 26342297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.